DEFA14A: Repare Therapeutics Acquired by XenoTherapeutics

Repare Therapeutics Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc. for an estimated US$1.82 per share plus one Contingent Value Right.

Summary

• Repare Therapeutics Inc. has entered into a definitive arrangement agreement to be acquired by XenoTherapeutics, Inc. for an estimated US$1.82 cash per common share.
• Shareholders will also receive one non-transferable Contingent Value Right (CVR) per common share, entitling them to future cash payments from existing partnerships and potential future asset monetizations for up to 10 years post-closing.
• The transaction is expected to close in the first quarter of 2026, pending shareholder and Superior Court of Quebec approvals.
• Repare's Board of Directors, following a unanimous recommendation from an independent Transaction Committee, has unanimously approved the transaction and recommends shareholders vote in favor.
• The company reported $112.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, an increase from $109.5 million at June 30, 2025.
• Third-quarter 2025 revenue from collaboration agreements was $11.6 million, a significant increase from nil in Q3 2024.
• Repare achieved a net income of $3.3 million, or $0.08 diluted per share, for Q3 2025, a substantial improvement from a net loss of $34.4 million in Q3 2024.
• Research and development expenses decreased to $7.5 million in Q3 2025 from $28.4 million in Q3 2024.
• Positive initial topline safety, tolerability, and early efficacy data for RP-1664 from its Phase 1 LIONS clinical trial were presented.
• Due to the acquisition, Repare will no longer be reporting initial topline data from the POLAR trial for its RP-3467 program.

Sentiment

Score: 7

Explanation: The definitive acquisition agreement provides a clear exit strategy and immediate cash, plus CVR upside, which is generally positive for shareholders of a clinical-stage company. Financial results for the quarter also showed significant improvement, moving from a net loss to a net income. However, the delisting of shares and the non-transferable nature of CVRs introduce limitations on liquidity and direct control over future asset monetization.

Positives

• The acquisition provides an immediate cash payment of an estimated US$1.82 per share to shareholders, offering liquidity.
• Shareholders retain potential upside through non-transferable Contingent Value Rights (CVRs) from existing partnerships and future asset monetizations for up to 10 years.
• The Board of Directors unanimously approved and recommended the transaction, indicating strong internal support and belief in its value.
• Repare reported a net income of $3.3 million ($0.08 diluted per share) for Q3 2025, a significant improvement from a net loss of $34.4 million in Q3 2024.
• Revenue from collaboration agreements increased to $11.6 million in Q3 2025 from nil in Q3 2024, demonstrating new revenue streams.
• Research and development expenses decreased substantially to $7.5 million in Q3 2025 from $28.4 million in Q3 2024, reflecting improved cost management or strategic prioritization.
• Cash, cash equivalents, and marketable securities increased to $112.6 million as of September 30, 2025, from $109.5 million at June 30, 2025, strengthening the balance sheet.
• Positive initial topline safety, tolerability, and early efficacy data for RP-1664 from the Phase 1 LIONS clinical trial were presented, supporting further investigation of the program.

Negatives

• The company will become privately held, and its shares will be delisted from Nasdaq, removing public trading liquidity for shareholders.
• The CVRs are non-transferable, limiting liquidity and making their value realization dependent on future events and XenoTherapeutics' efforts.
• Repare will no longer be reporting initial topline safety, tolerability, and early efficacy data from the POLAR trial for RP-3467, halting public updates on this program.
• A termination fee of US$2.0 million is payable by Repare under certain circumstances, including if it enters into a definitive agreement for a Superior Proposal.
• The transaction involves significant transaction costs and unknown liabilities that could impact the final cash payment to shareholders.

Risks

• The completion of the Transaction is subject to various conditions, including required shareholder and court approvals, which may not be obtained on anticipated terms or timing.
• Potential litigation relating to the Transaction could be instituted by or against the Company, Xeno, XOMA Royalty, or their respective directors or officers.
• Significant transaction costs and unknown liabilities are associated with the Transaction, which could reduce the final cash payment to shareholders.
• The actual amounts payable under the CVRs are contingent on future events, including the success of existing partnerships and the ability to license or dispose of product candidates and intellectual property, which may not materialize as expected.
• The ability to enter into or complete any potential transactions to license or dispose of product candidates and/or intellectual property related to its RP-3467 and Polq program, RP-1664 program, RP-3500 (Camonsertib) program, and/or other product candidates and research programs is uncertain.

Future Outlook

The transaction is expected to close in the first quarter of 2026, subject to shareholder and court approvals. Repare continues to seek opportunities to license or dispose of its product candidates and intellectual property, with any proceeds prior to closing potentially increasing the cash payment to shareholders. Following the acquisition, Repare will become a privately held company, and its shares will be delisted from Nasdaq.

Management Comments

• "Following a thorough and wide-ranging strategic review of potential opportunities, partnerships and transactions aimed at maximizing shareholder value, Repare’s Board of Directors has unanimously determined that the Transaction is in the best interests of Repare and its various stakeholders." Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare.
• "The Transaction provides a cash payment to shareholders and the opportunity for continued participation in milestones and royalties from existing and potential future partnerships." Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare.
• "On behalf of the Company, I would like to acknowledge and thank our employees for their dedication and exceptional service." Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare.

Industry Context

This acquisition reflects a trend in the biotechnology and precision oncology sector where smaller clinical-stage companies, after conducting strategic reviews, opt for acquisition by larger entities or non-profits to maximize shareholder value, especially when facing significant R&D costs and market pressures. The inclusion of CVRs is a common mechanism to bridge valuation gaps and allow selling shareholders to participate in the future success of pipeline assets without the ongoing operational risks of a public company. XenoTherapeutics, as a non-profit, may have different strategic drivers for acquiring Repare's assets, potentially focusing on long-term research and development rather than immediate commercial returns, which could be attractive for certain therapeutic programs.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in this acquisition is a common mechanism in biotech M&A, particularly for clinical-stage companies, to provide shareholders with potential upside from pipeline assets that have not yet reached commercialization. This structure was notably used in the acquisition of Synageva BioPharma by Alexion Pharmaceuticals and the acquisition of Spark Therapeutics by Roche, where CVRs were tied to regulatory approvals or sales milestones.
• The estimated cash payment of US$1.82 per share, combined with CVRs, suggests a valuation that attempts to balance immediate liquidity with the long-term, uncertain value of Repare's precision oncology pipeline, including RP-1664 and RP-3467. This is typical for companies with promising but early-stage assets.
• The unanimous recommendation by an independent Transaction Committee and the full Board of Directors, following a strategic review, aligns with best practices in corporate governance for M&A transactions, aiming to ensure the deal is in the best interest of shareholders.
• The significant reduction in R&D expenses from $28.4 million to $7.5 million quarter-over-quarter, alongside a shift from a net loss to a net income, indicates a strong focus on cost control or a strategic winding down of certain internal R&D efforts in anticipation of the acquisition, which is a common pre-acquisition financial adjustment.

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive an estimated US$1.82 cash per share and one non-transferable CVR per share, offering immediate liquidity and potential future upside from pipeline assets. However, they will lose direct ownership in a publicly traded company and the liquidity of their shares.
• Employees: The filing mentions management acknowledging and thanking employees for their dedication, but does not detail specific impacts on employment or roles post-acquisition.
• Partners (Bristol-Myers Squibb, Debiopharm, DCx Biotherapeutics): Existing partnerships will continue, with a percentage of net proceeds flowing to CVR holders, indicating continuity for these collaborations under XenoTherapeutics' ownership.
• Customers/Patients: The continued development of product candidates under XenoTherapeutics, particularly RP-1664, suggests ongoing efforts to bring new precision oncology therapies to patients. The halt of public updates on RP-3467's POLAR trial might affect transparency for the medical community regarding that specific program.

Next Steps

• Repare will file a proxy statement on Schedule 14A with the SEC and furnish it to shareholders.
• A special meeting of shareholders will be held to seek required approvals for the Transaction (66 2/3% of votes cast and a majority of votes excluding certain interested parties).
• The Superior Court of Quebec must approve the plan of arrangement.
• The transaction is expected to close in the first quarter of 2026.
• Following completion, Repare will become a privately held company, delisted from Nasdaq, and will apply to cease being a reporting issuer under Canadian securities laws and deregister under the U.S. Securities Exchange Act of 1934.
• Repare continues to endeavor to license or dispose of its product candidates and/or intellectual property related to its RP-3467 and Polq program, RP-1664 program, RP-3500 (Camonsertib) program, and/or any other product candidates or research programs.

Key Dates

Recommendation

The definitive agreement to be acquired provides a clear exit for shareholders with an estimated cash payment of US$1.82 per share and non-transferable Contingent Value Rights (CVRs). While the CVRs offer potential future upside, their non-transferable nature limits liquidity. Given the transaction is subject to shareholder and court approvals and is expected to close in Q1 2026, holding the shares until the closing allows investors to receive the cash and CVRs. The current share price will likely trade close to the estimated cash value plus a discounted value of the CVRs, making significant short-term gains unlikely unless a superior offer emerges, which is protected by a termination fee. Selling now would forgo the CVRs and any potential slight premium if the market values the CVRs higher than current trading. Buying now would be speculative on the CVR value or a superior offer.

Keywords

Repare Therapeutics, XenoTherapeutics, Acquisition, Merger, Biotechnology, Oncology, Precision Oncology, Synthetic Lethality, RP-1664, RP-3467, Contingent Value Right, RPTX, Q3 2025 Financials